Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$22.48

52W Range

$14.12 - $28.15

50D Avg

$25.42

200D Avg

$21.57

Market Cap

$1.55B

Avg Vol (3M)

$358.55K

Beta

0.32

Div Yield

-

KNSA Company Profile


Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

BM

Employees

297

IPO Date

May 25, 2018

Website

KNSA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22
Product$233.18M$122.52M
Collaboration$37.08M$97.66M

Fiscal year ends in Dec 23 | Currency in USD

KNSA Financial Summary


Dec 23Dec 22Dec 21
Revenue$270.26M$220.18M$38.54M
Operating Income$-25.20M$7.37M$-156.64M
Net Income$-47.39M$183.36M$-157.92M
EBITDA$-25.20M$9.77M$-156.64M
Basic EPS-$2.64$-2.30
Diluted EPS-$2.60$-2.30

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Oct 29, 24 | 11:45 AM
Q2 24Jul 23, 24 | 1:30 PM
Q1 24Apr 23, 24 | 1:59 PM

Peer Comparison


TickerCompany
GRCLGracell Biotechnologies Inc.
NUVLNuvalent, Inc.
GOSSGossamer Bio, Inc.
CGEMCullinan Oncology, Inc.
LRMRLarimar Therapeutics, Inc.
DAWNDay One Biopharmaceuticals, Inc.
PHATPhathom Pharmaceuticals, Inc.
VTYXVentyx Biosciences, Inc.
CERECerevel Therapeutics Holdings, Inc.
COGTCogent Biosciences, Inc.
SPROSpero Therapeutics, Inc.
REPLReplimune Group, Inc.
KRONKronos Bio, Inc.
BOLTBolt Biotherapeutics, Inc.
ACLXArcellx, Inc.
GPCRStructure Therapeutics Inc.
NLTXNeurogene Inc.
KURAKura Oncology, Inc.
CHRSCoherus BioSciences, Inc.
KRTXKaruna Therapeutics, Inc.
LYRALyra Therapeutics, Inc.
NVCTNuvectis Pharma, Inc.